Physician profile
Caleb Lee
NPI 1023201977
$624.80
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $200.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $181.18 | 2019-2020 | |
| Abbvie INC. | $61.82 | 2019-2020 | |
| Lilly USA, LLC | $57.09 | 2019-2020 | |
| Amgen INC. | $46.85 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $44.23 | 2019 | |
| Prugen, INC. Pharmaceuticals | $40.10 | 2019 | |
| Genzyme Corporation | $36.03 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.41 | 2019 | |
| Ucb, INC. | $19.83 | 2019 | |
| Dusa Pharmaceuticals, INC. | $19.35 | 2019 | |
| Leo Pharma INC. | $18.82 | 2019 | |
| Dermira, INC. | $18.73 | 2020 | |
| Pfizer INC. | $18.63 | 2019 | |
| Biofrontera INC. | $15.45 | 2020 | |
| Merck Sharp & Dohme LLC | $15.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.